[Current problems in active substance research. 4. Central effects of angiotensin II].
D000305:Adrenal Cortex Hormones / Q000378:metabolism; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002415:Cats; D002490:Central Nervous System / Q000187:drug effects*; D004285:Dogs; D004336:Drug Antagonism; D004347:Drug Interactions; D004357:Drug Synergism; D006339:Heart Rate / Q000187:drug effects; D006973:Hypertension / Q000503:physiopathology; D008322:Mammals; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D009842:Oligopeptides / Q000494:pharmacology; D011311:Pressoreceptors / Q000187:drug effects; D011817:Rabbits; D051381:Rats; D013268:Stimulation, Chemical; D009435:Synaptic Transmission / Q000187:drug effects; D014520:Urethane / Q000494:pharmacology; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D000305:Adrenal Cortex Hormones; D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D009842:Oligopeptides; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D014520:Urethane; D009638:Norepinephrine
Aktuelle Probleme der Wirkstofforschung. 4. Zentrale Wirkungne von Angiotensin II